Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 23246678 | HLA (HLA) | prostate cancer | NA | NA | NA | unclassified | |
| in vitro, the prostate cancer cell (pc-3 cells) infected with lentivirus tap1 can efficiently over-express tap1 and tapasin, and hla-1 was also up-regulated on the surface of the infected cells. | |||||||
| 23609828 | HLA (HLA) | prostate cancer | NA | NA | NA | unclassified | |
| hla-restricted ny-eso-1 peptide immunotherapy for metastatic castration resistant prostate cancer. | |||||||
| 23609828 | HLA (HLA) | prostate cancer | NA | NA | NA | unclassified | |
| given the immunogenicity of ny-eso-1 peptides in prostate cancer, a phase i clinical trial was designed to evaluate hla class-i and class-ii restricted ny-eso-1 peptides in metastatic castration-resistant prostate cancer (mcrpc). | |||||||
| 23721092 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| hla-a2-restricted cytotoxic t lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy. | |||||||
| 23721092 | HLA-A*02 | prostate cancer | NA | NA | NA | only_studied | |
| hla-a2-restricted ctl epitopes were identified using the following four-step procedure: (1) a computer program generated predicted epitopes from the amino acid sequence of human hepsin | |||||||
| 23721092 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| the effectors that were induced by human hepsin epitopes containing residues 229 to 237 (hpn229; glqlgvqav), 268 to 276 (hpn268; plteyiqpv) and 191 to 199 (hpn199; sllsgdwvl) effectively lysed lncap prostate cancer cells that were hepsin-positive and hla-a2 matched. | |||||||
| 24149465 | HLA-A*02 | prostate cancer | NA | NA | NA | unclassified | |
| finally, tetramer assay showed detectable and responsive erg295-specific cytotoxic lymphocytes in peripheral blood of hla-a*0201(+) prostate cancer patients. | |||||||
| 25085000 | HLA-DR (HLA-DR) | prostate cancer | NA | lactate | NA | positive | |
| investigating the frequency and function of immune suppressive cell subsets in the peripheral blood of 41 patients with prostate cancer (pc) and 36 healthy donors (hd) showed a significant increase in circulating cd14(+) hla-dr(low/neg) monocytic mdsc (m-mdsc) and tregs in patients with pc compared to hd. | |||||||
| 25111463 | HLA-DR (HLA-DR) | prostate cancer | NA | NA | NA | unclassified | |
| breaking immune tolerance by targeting cd25+ regulatory t cells is essential for the anti-tumor effect of the ctla-4 blockade in an hla-dr transgenic mouse model of prostate cancer. | |||||||
| 25239560 | HLA (HLA) | prostate cancer | NA | NA | NA | unclassified | |
| a prostate cancer cell line candidate for cancer therapy (p4e6) was used and cell surface markers cd9, cd147 and hla a-c were investigated. | |||||||
Copyright 2024